<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745728</url>
  </required_header>
  <id_info>
    <org_study_id>iMN cohort</org_study_id>
    <nct_id>NCT04745728</nct_id>
  </id_info>
  <brief_title>Different Immunosuppressive Treatment in iMN</brief_title>
  <official_title>Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the 24 month remission of different&#xD;
      immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the first-line immunosuppressive immunosuppressive therapy of iMN includes&#xD;
      corticosteroids combined with cyclophosphamide or rituximab (RTX). In recent randomized&#xD;
      trials (MENTOR, GEMRITUX), the long-term remission rate of RTX is about 60%, which is similar&#xD;
      to the remission rate of cyclophosphamide combined with corticosteroids in early studies. But&#xD;
      there is only one published randomized trial (STARMEN) comparing the efficacy of the two&#xD;
      protocols head-to-head. In STRAMEN trial, the long-term remission rate of&#xD;
      cyclophosphamide+corticosteroids group was 83%, which was significantly higher than the that&#xD;
      (58%) of the tacrolimus-RTX group. But in STRAMEN trial, only one single dose of RTX was&#xD;
      given which might influence the efficacy of the tacrolimus-RTX arm. Therefore, head-to-head&#xD;
      comparison of RTX (more than one dose) and cyclophosphamide+corticosteroid is needed. The&#xD;
      optimal dose of RTX in the treatment of iMN is unclear. In MENTOR trial, RTX was given 1g on&#xD;
      D1 and D15, and the rate of complete remission at 6 month was 0, so RTX was repeated at 6&#xD;
      month. Based on the experience of our center, most patients need at least one repeated dose&#xD;
      of RTX at 6 month.&#xD;
&#xD;
      Based on the previous rationale, the investigators designed this study to compare the&#xD;
      efficacy of cyclophosphamide plus corticosteroids with RTX in the treatment of iMN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete or partial remission on 24 month</measure>
    <time_frame>24 months</time_frame>
    <description>Complete remission is defined as urine protein &lt; 0.5g/24h and serum albumin≥ 3.5g/dl. Partial remission is defined as reduction in urine protein≥50% plus urine protein ≤3.5g/24h but &gt;0.5g/24h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete or partial remission on 6, 12 and 18 month</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <description>complete or partial remission on 6, 12 and 18 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission on 6, 12, 18 and 24 month</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>complete remission on 6, 12, 18 and 24 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to complete or partial remission</measure>
    <time_frame>from date of treatment until the date of first documented remission, up to 24 months</time_frame>
    <description>time to complete or partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>24 months</time_frame>
    <description>change of estimated glomerular filtration rate (eGFR) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine increase ≥50 percent from baseline</measure>
    <time_frame>24 months</time_frame>
    <description>proportion of patients with increase of serum creatinine ≥50 percent from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of relapse</measure>
    <time_frame>12, 18, 24 months</time_frame>
    <description>proportion of patients with relapse. Relapse is defined as development of urine protein &gt;3.5g/24h following complete or partial remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-PLA2R levels</measure>
    <time_frame>baseline and 3, 6, 9, 12, 18, 24 months</time_frame>
    <description>Auto-antibody to the M-type phospholipase A2 receptor (PLA2R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD19+ B cell count</measure>
    <time_frame>baseline and 3, 6, 9, 12, 18, 24 months</time_frame>
    <description>CD19+ B cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through the study completion until 24 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>cyclophosphamide and prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone will be given at 1mg/kg/d p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.&#xD;
Cyclophosphamide will be given at 1-2mg/kg/d p.o. with a target accumulated dose of 12g.&#xD;
Azathioprine or mycophenolate mofetil are optional which could be given for a short period of time (&lt;6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count&gt;5/ul on the 15th day.&#xD;
Calcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.</description>
    <arm_group_label>cyclophosphamide and prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1-2mg/kg/d p.o. with a target accumulated dose of 12g.</description>
    <arm_group_label>cyclophosphamide and prednisone</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count&gt;5/ul.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>CD20 antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  idiopathic membranous nephropathy&#xD;
&#xD;
          -  Female, must be post-menopausal, sterile or have effective contraception&#xD;
&#xD;
          -  must be off steroid or mycophenolate mofetil for &gt;1 month and alkylating agents for or&#xD;
             RTX&gt; 6 months&#xD;
&#xD;
          -  Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)&#xD;
             for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive&#xD;
             therapy or if patients are intolerant to ACEI/ARB.&#xD;
&#xD;
          -  proteinuria ≥4g/24h and decreased ≤ 50% from baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of active infection or a secondary cause of membranous nephropathy&#xD;
&#xD;
          -  proteinuria associated with diabetic nephropathy&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  history of resistance to rituximab or alkylating agents or corticosteroid&#xD;
&#xD;
          -  Patients who previously achieved remission after treatment of rituximab or alkylating&#xD;
             agents but relapsed off rituximab or alkylating agents after 6 months are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Qin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanxi Ai</last_name>
    <phone>18811054896</phone>
    <email>sanxiai@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Qin</last_name>
    <email>qinyanbeijing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanxi Ai</last_name>
      <email>sanxiai@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Qin</last_name>
      <email>qinyanbeijing@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Miao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010 Apr;21(4):697-704. doi: 10.1681/ASN.2009080861. Epub 2010 Jan 28.</citation>
    <PMID>20110379</PMID>
  </reference>
  <reference>
    <citation>Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27.</citation>
    <PMID>27352623</PMID>
  </reference>
  <reference>
    <citation>Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.</citation>
    <PMID>31269364</PMID>
  </reference>
  <reference>
    <citation>van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.</citation>
    <PMID>28487395</PMID>
  </reference>
  <reference>
    <citation>Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M; STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.</citation>
    <PMID>33166580</PMID>
  </reference>
  <reference>
    <citation>Dahan K, Johannet C, Esteve E, Plaisier E, Debiec H, Ronco P. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Kidney Int. 2019 Jan;95(1):233-234. doi: 10.1016/j.kint.2018.08.045.</citation>
    <PMID>30606419</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

